Electroconvulsive therapy (ECT) uses a brief, controlled electrical stimulus to the scalp, under general anesthesia and muscle relaxation, to produce a generalized seizure. The exact mechanism is not fully known; the induced seizure causes widespread changes in neurotransmitter systems (serotonin, norepinephrine, dopamine, GABA), neuroendocrine function, and neuroplasticity. It does not destroy brain tissue and is not a "psychological shock." ECT is one of the most effective and fastest treatments for severe depression.
Indications
- Severe major depression (unipolar or bipolar), especially treatment-resistant, psychotic depression, or when a rapid response is needed (high suicide risk, refusal to eat or drink, catatonic stupor)
- Catatonia (when benzodiazepines fail)
- Acute mania not responding to medication
- Schizophrenia with catatonia, prominent affective symptoms, or clozapine resistance
- Neuroleptic malignant syndrome; when medications are unsafe (e.g., some pregnancies, older adults who cannot tolerate drugs)
ECT is not a primary treatment for OCD, personality disorders (e.g., borderline), or anxiety disorders.
Contraindications: no absolute contraindications, but risk is high with increased intracranial pressure or a space-occupying brain lesion, recent myocardial infarction or unstable heart disease, recent stroke, intracranial aneurysm or vascular malformation, pheochromocytoma, severe pulmonary disease, and high anesthesia risk.
Before ECT
- Psychiatric status, suicide risk, baseline cognition and memory (e.g., MoCA)
- Medical history: cardiac, neurologic, pulmonary, dental (loose teeth), previous anesthesia problems, malignant hyperthermia or pseudocholinesterase deficiency history
- Current medications (see Section 4)
- Vital signs, weight, NPO status, pregnancy status
During the procedure (typical physiologic sequence)
- Brief bradycardia (vagal) at stimulus, then tachycardia and hypertension during the seizure
- Tonic-clonic seizure largely masked by the muscle relaxant; seizure length monitored by EEG (and often a cuff on one limb that blocks the relaxant)
After ECT
- Airway, breathing, oxygen saturation, vital signs
- Postictal confusion and disorientation, headache, muscle aches, nausea
- Memory impairment: anterograde (difficulty learning new information after treatments) and retrograde (gaps for events around the treatment period)
| Test | Purpose |
|---|
| History and physical, anesthesia evaluation | Assess procedural risk |
| ECG | Cardiac status (especially older adults or heart disease) |
| CBC, electrolytes (potassium, sodium), glucose, kidney function; pregnancy test | Anesthesia safety |
| Chest X-ray, spine films, brain imaging | Only when clinically indicated (lung disease, prior spinal injury, neurologic signs) |
| Baseline and serial cognitive testing | Track cognitive side effects |
| EEG during treatment | Confirms adequate seizure |
| Rating scales (PHQ-9, HAM-D) | Measure response |
Course of treatment
- Usually 2–3 times per week, typically 6–12 treatments in the acute course
- Improvement usually begins after several treatments (often 3–6); one or two treatments are not expected to produce full effect
- Continuation or maintenance ECT and/or medication prevents relapse
Electrode placement
| Placement | Features |
|---|
| Right unilateral (often ultrabrief pulse) | Fewer cognitive and memory side effects (spares the language-dominant left hemisphere); commonly first choice |
| Bilateral (bitemporal) | Faster, more robust response; more cognitive effects; used for urgent or resistant cases |
| Bifrontal | Intermediate option |
Medications used during ECT
| Drug | Purpose | Safety points |
|---|
| Anticholinergic (glycopyrrolate or atropine) | Reduces secretions (aspiration risk) and prevents vagal bradycardia/asystole | Tachycardia, urinary retention; caution in narrow-angle glaucoma |
| Anesthetic (methohexital, propofol, etomidate, ketamine) | Brief general anesthesia | Hypotension, respiratory depression; propofol and benzodiazepine-like drugs raise seizure threshold |
| Muscle relaxant (succinylcholine) | Prevents fractures, dislocations, and injury from the convulsion | Postoperative myalgia; malignant hyperthermia trigger; hyperkalemia in burns, crush injury, neuromuscular disease, prolonged immobility; prolonged apnea with pseudocholinesterase deficiency |
| Beta blocker (labetalol, esmolol) | Controls hypertension and tachycardia | Bradycardia, bronchospasm in asthma |
| Oxygen, bite block | Oxygenation; protect teeth and tongue | — |
Pre-ECT medication adjustments (by prescriber)
- Benzodiazepines and anticonvulsants (including valproate, lamotrigine) raise the seizure threshold — doses are reduced or held
- Lithium — increases risk of post-ECT delirium and prolonged seizures; often held or reduced
- Theophylline — risk of prolonged seizures
- Essential cardiac and antihypertensive drugs are usually given with a sip of water the morning of treatment as ordered
Other brain stimulation and rapid-acting treatments
| Treatment | Key facts |
|---|
| Transcranial magnetic stimulation (TMS) | Magnetic pulses over the left prefrontal cortex; no anesthesia, no seizure intended, client awake and can drive home; usually daily on weekdays for about 4–6 weeks. Adverse effects: scalp discomfort, headache; rare seizures. Contraindicated with non-removable metal in or near the head (aneurysm clips, cochlear implants). Accelerated MRI-guided protocol (SAINT, cleared 2022) delivers multiple sessions daily over 5 days. Cleared in 2024 as an adjunct for depression in adolescents aged 15–21. Deep TMS is also cleared for OCD and smoking cessation |
| Vagus nerve stimulation (VNS) | Implanted pulse generator stimulating the left vagus nerve; long-term adjunct for chronic treatment-resistant depression; hoarseness, cough, voice change |
| Deep brain stimulation | Implanted electrodes; limited psychiatric use (severe OCD under humanitarian approval) |
| Esketamine nasal spray | Treatment-resistant depression (with an oral antidepressant or, since 2025, as monotherapy) and depression with acute suicidal ideation. Given only in a certified setting under a REMS with at least 2 hours of monitoring for sedation, dissociation, respiratory depression, and increased blood pressure. Contraindicated in aneurysmal vascular disease, arteriovenous malformation, and intracerebral hemorrhage history. Abuse potential; boxed warning for suicidality as with antidepressants. No driving until the next day after restful sleep |
| Bright light therapy | About 10,000 lux for 20–30 minutes each morning for depression with a seasonal pattern; can trigger mania in bipolar disorder; caution with photosensitizing drugs |
Listed in priority order.
Before ECT
- Verify written informed consent (the client may withdraw consent at any time) and that questions were answered
- NPO per anesthesia protocol — commonly no solid food for 6–8 hours; clear liquids may be allowed until about 2 hours before, per agency policy
- Baseline vital signs, ECG, labs, weight; confirm medication adjustments
- Have the client void; remove dentures, glasses, contact lenses, jewelry, hairpins; hair clean and dry without products (electrode contact)
- Place IV access; reassure and stay with the client to reduce anxiety
After ECT (recovery)
- Airway first: maintain airway, side-lying position until fully awake (aspiration risk), oxygen, suction ready
- Vital signs and SpO₂ frequently (e.g., every 15 minutes) until stable; watch for dysrhythmias, hypertension, prolonged apnea
- Monitor for prolonged seizure and report
- Reorient calmly and repeatedly: introduce yourself, tell the client where they are and that treatment is finished; stay with a confused client; do not quiz memory immediately
- Fall precautions — assist with first ambulation
- Check gag reflex before giving fluids and food; give analgesic for headache or myalgia as ordered
- ECT is done under anesthesia; the client does not feel pain and is asleep during the seizure
- Expect temporary confusion, headache, muscle aches, and memory gaps around the treatment period; most memory problems improve over weeks to months, though some memories from that period may not return
- Improvement typically appears after several treatments, not immediately
- Do not drive, sign important documents, or make major decisions during the acute course
- An adult should accompany outpatients home
- Keep a journal or calendar to help with memory; continue medications or maintenance treatment as planned
| Complication | Nursing action |
|---|
| Airway obstruction, aspiration, respiratory depression (immediate) | Airway support, suction, oxygen |
| Dysrhythmias, hypertension, myocardial ischemia | Cardiac monitoring; notify provider |
| Prolonged seizure (beyond about 2–3 minutes) or status epilepticus | Terminate per protocol (IV anesthetic or benzodiazepine) |
| Post-ECT delirium | Safety, reorientation; review lithium and other drugs |
| Prolonged apnea | Ventilatory support (pseudocholinesterase deficiency) |
| Malignant hyperthermia | Rising end-tidal CO₂, rigidity, fever → dantrolene |
| Dental or tongue injury | Bite block; dental assessment |
| Switch to mania (bipolar) | Monitor mood during course |
- ECT = induced generalized seizure under anesthesia and muscle relaxation; changes neurotransmitter systems
- Best indication: severe or treatment-resistant depression, psychotic depression, high suicide risk, catatonia; also mania
- Not first-line for OCD or personality disorders
- Anticholinergic premedication: decreases secretions and prevents bradycardia
- Succinylcholine prevents fractures and dislocations; causes myalgia
- Right unilateral placement = fewer memory side effects
- Course: 2–3 times weekly, about 6–12 treatments; response after several treatments
- Most common side effects: transient memory loss, confusion, headache, myalgia
- After ECT: airway and vital signs first, side-lying, then reorientation
- Benzodiazepines and anticonvulsants raise seizure threshold; lithium increases post-ECT delirium
- TMS: no anesthesia, awake, outpatient; esketamine: REMS with 2-hour monitoring
Country Notes
United States
- Since 2018, FDA classifies ECT devices as class II for catatonia and severe major depressive episodes in major depressive or bipolar disorder in people 13 years and older who are treatment-resistant or need a rapid response.
- Many states have specific consent rules for ECT (for example, court review for clients who lack capacity or are minors).
Philippines
- Under the Mental Health Act (RA 11036), written informed consent is required before any treatment; in an emergency or with impaired decision-making capacity, treatment without consent must follow the Act's safeguards, including internal review board review within 15 days.